Anti-GPC3 chimeric antigen receptor T cell therapy (Shanghai Genechem)

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameAnti-GPC3 chimeric antigen receptor T cell therapy (Shanghai Genechem)
Drug Alias NameGPC3-CART cellsTAI-GPC3-CART cells - Shanghai GenechemCAR (hYP7)-T cellsGB-5011
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsWnt signalling pathway inhibitors +[4] 
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Genechem Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Genechem Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A